AI could ease oncology's drug development "traffic jam," while biomarker subsetting drives more personalized cancer care, David Spigel, MD, says.
David Spigel, MD
Advertisement
David Spigel, MD, is the president and chief medical officer of Sarah Cannon Research Institute.
Articles by David Spigel, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5